NCT05860595View on ClinicalTrials.gov

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

NAActive, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

August 20, 2025

Study Completion Date

October 24, 2025

Conditions
Transfusion-dependent Beta-Thalassemia
Interventions
GENETIC

KL003 cell injection Drug Product

Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.

Trial Locations (1)

Unknown

Regenerative Medicine Center, Tianjin

All Listed Sponsors
collaborator

R&D Kanglin Biotech

OTHER

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER